Related Experiment Video
Updated: Sep 13, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in
Anuradha Nadda1, Neha Kapoor1, Sahil Sharma1
1Department of Community Medicine, Dr. B. R. Ambedkar State Institute of Medical Sciences, Mohali, Punjab, India.
Introduction:
Breakthrough infections (BTI) threaten the progress of the COVID-19 vaccination program towards pandemic control. To better understand the future vaccine, knowing the BTI in the general population over a while is important.
Aims And Objectives:
The study aimed to compare the BTI among the general population after 1 year of completion of the primary series of Covishield and Covaxin.
Materials And Methods:
This hospital-based prospective study was conducted among the general population beneficiaries of a COVID-19 vaccination center. Clients aged 18 years or above who had completed second vaccine dose were enrolled using systematic random sampling and followed up for 1 year. Using a semi-structured questionnaire, participants were telephonically interviewed within 1 month, 6 months, and 12 months of the second vaccine dose.
Results:
Out of 1682 participants who completed the study, 958 (57.0%) and 724 (43.0%) participants received Covaxin and Covishield, respectively. Twenty-nine (3.0%) Covaxin recipients and 25 (3.5%) Covishield recipients reported BTI after 1 year of follow-up with no statistically significant difference among both groups (p-0.624). The binary logistic regression model showed that participants with either diabetes or hypertension had 1.22 times the risk of BTI compared to those without comorbidities (aOR: 1.219, CI: 0.072-20.716, p-0.891). BTI was not significantly associated with the type of vaccine, sex, employment status, and age category of the participants.
Conclusion:
The study suggests that regardless of the type of vaccine received, the population will be at the same risk and require similar future containment strategies.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:08Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
01:28Antimicrobial Effectiveness
01:16Bioequivalence: Overview